Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Get key Q3 2025 earnings insights for Lulu's (LVLU): margin gains, strategic shifts, improved EBITDA, and growth drivers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback